Industry S Science News
It’s not just the U.S. Measles is roaring back around the globe
Eroding trust, decreased funding, and political strife have fanned the flames of a viral disease that’s easy to prevent
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry S Science News
Eroding trust, decreased funding, and political strife have fanned the flames of a viral disease that’s easy to prevent
Regulatory
BioCentury
BIOCENTURY | REGULATIONFDA HOLDS SUMMIT TO SURVIVAL BAR IN IVONESCIMAB CRLLonger follow-up helped answer a question about the drug’s activity in Western patients, but the primary analysis fell short in EGFR-mutant NSCLC
Manufacturing N Nature Medicine
Manufacturing B BioProcess International
Experts were amazed the trial planned received approval from the University of Southern Denmark despite major red flags. So was one of the lead reviewers.
Industry
BioCentury
BIOCENTURY | DEALSPAIR OF LILLY DEALS INCLUDES TAKEOUT OF STEALTHY CALYTRIX FOR UP TO $1.5B: DEALS REPORTPlus: J&J/Ollin, Vor/RemeGen, BioNTech/Scholar Rock, and more
Industry
GEN
In lab-grown human neurons and organoids carrying CHD8 or SCN2A mutations, researchers reduced organoid overgrowth and moved neuronal electrical activity closer to wild-type levels. The post Enhancer-Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model appeared fir…
Industry
BioCentury
BIOCENTURY | DEALSAFTER GENE THERAPY SETBACKS, J&J PAYS $2.2B FOR OLLIN, ADDS RETINAL DISEASE CANDIDATEFunding arrangement with Blackstone to support Phase III testing of treatment that could compete with blockbuster Vabysmo
Industry
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTRARE DISEASE SPOTLIGHT: ATTACKING THE SAME BLEEDING PROBLEM FROM FOUR DIRECTIONSEngasertib leads in Phase III while newer programs target plasminogen, ALK1, and vessel stability
Regulatory
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTLEXEO PLANS PIVOTAL GENE THERAPY TRIAL AIMED AT ACCELERATED APPROVALBioCentury’s Clinical Report, Nov. 10–16
Software D Diamond Age Data Science
Challenge: Lots of data, limited bandwidth and budget A small, early-stage oncology biotech came to Diamond Age Data Science with a common problem for a company of their size: minimal staff, a limited budget, and a significant amount of untapped data. They knew they had the data…
Software P Paired Ends
Operational safety is not the same as biosecurity
Industry
GEN
In this GEN podcast, the third in a series, LabVantage’s Denise Bell discusses how laboratories can reduce operational fragmentation and build connected, scalable operations. The post Toward Connected Laboratory Ecosystems appeared first on GEN - Genetic Engineering and Biotechno…
Software
MedTech Dive
The tech juggernaut and clinical AI company will research what drives consumer trust and the quality of health AI responses, among other areas. Apple could use the findings to inform product development.
Industry
GEN
Researchers studying how gut microbes modify bile acids have identified changes in the metabolic activity of the gut microbiome associated with exceptional longevity in humans, and found that amplifying the same activity with engineered bacteria improved metabolic health in aged…
Industry
C&EN Pharmaceuticals
The hype and promise of these drugs reflect the challenge of inclusive problem-solving when the stakes are high
Industry
C&EN Pharmaceuticals
The hype and promise of these drugs reflect the challenge of inclusive problem-solving when the stakes are high
Industry P pharmaphorum
Novo says Wegovy shot works in childhood obesity Phil.Taylor Mon, 16/11/2026 - 20:19
Industry
Inside Precision Medicine
A new study suggests that combining blood protein profiling with routine clinical measurements could improve the identification of people at risk of diabetes and other chronic diseases. The post Blood Protein Signature Could Improve Diabetes and Cardiometabolic Risk Prediction ap…
Regulatory P Pharmaceutical Executive
FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kevin Caldwell joins The Ron Lanton Report on rebuilding bone marrow transplants around deceased-donor marrow.
Industry
Inside Precision Medicine
Exposure to the wartime chemical herbicide Agent Orange significantly increased risk for developing Parkinson's disease and other synucleinopathies in later life. The post Exposure to Agent Orange Increased Risk for Parkinson’s Disease appeared first on Inside Precision Medicine.
Regulatory B BioPharm International
In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.
Clinical A Applied Clinical Trials
Participants in a survey of 354 pre-screening respondents rated AI voice-assisted screening (Clara) favorably and were more likely to schedule and attend study appointments than web-form users, though self-selection means the association cannot be read as causal.
Clinical P pharmaphorum
Helus shares slide on psychedelic readout in depression Phil.Taylor Mon, 16/11/2026 - 19:07
Agriculture
AgriBusiness Global
Deal establishes an immediate leadership position in Egypt and creates a strong platform for further growth across the Middle East and Africa. The post Advanta To Strengthen Market Presence in Africa with Strategic Acquisition of Hytech appeared first on AgriBusiness Global.
Funding
MedCity News
Johnson & Johnson’s Ollin Biosciences acquisition comes with a Phase 3-ready bispecific antibody. The companies say this eye drug offer advantages over Vabysmo, a Roche drug approved for wet age-related macular degeneration and diabetic macular edema. The post J&J’s $2.2B…
Regulatory
STAT Biotech
The supplement NAC has been widely available for years, but exists in a legal grey area.
Regulatory B BioPharm International
FDA issues a complete response letter for Summit Therapeutics’ PD-1/VEGF bispecific ivonescimab in EGFR-mutated non-small cell lung cancer, approves Roche’s obinutuzumab (Gazyva) for primary membranous nephropathy, and approves AstraZeneca’s nanobody C5 inhibitor gefurulimab (Kly…
Agriculture
AgriBusiness Global
The flucarbazone-sodium formulation is designed to deliver grass and broadleaf weed control in wheat while improving tank mix performance and handling. The post U.S.: Nufarm Announces EPA Registrations for Mountain Herbicide appeared first on AgriBusiness Global.
Industry P Pharmaceutical Commerce
In Episode 1, Part 4, Jon Hamrick, Rena Goins and Bob Cochran explain what separates trade teams seen as strategic partners from those that aren't.
Regulatory
Drug Delivery Business
After submitting its patch pump for FDA review in late August, MiniMed (Nasdaq: MMED) has turned around a quick clearance for the Fit automated insulin delivery system. The Fit marks the company’s first tubeless design, carrying a 300-unit insulin capacity and a seven-day wear ti…
Funding P Pharmaceutical Executive
New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.
Industry
Fierce Biotech
The Adaptive HCP Engagement Playbook Explore how adaptive HCP engagement and AI-driven strategies can help pharma teams move beyond static segmentation and strengthen omnichannel marketing. Download now. sdees Mon, 11/16/2026 - 12:27 Explore how adaptive HCP engagement and AI-dri…
Regulatory B BioPharm International
FDA declined to approve Summit Therapeutics and Akeso’s ivonescimab plus chemotherapy in previously treated EGFR-mutated NSCLC. The agency said the Phase 3 HARMONi trial’s progression-free survival benefit was not enough without a significant overall survival gain.
Regulatory
BioPharma Dive
The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
Regulatory B BioPharm International
Obinutuzumab produced complete proteinuria remission in 36.1% of primary membranous nephropathy patients at 2 years vs 5.7% with tacrolimus.
Industry
Pharmaceutical Technology
The deal sees J&J bolster its pipeline with a bispecific antibody in Phase III development for wAMD and DME.
Clinical
BioPharma Dive
CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
Industry
BioPharma Dive
The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
Industry
STAT Biotech
Biotech is having a good year, though you wouldn't necessarily know it from how investors are treating positive clinical data.
Regulatory P Pharmaceutical Executive
FDA approves Genentech’s Gazyva, Alexion’s Klygefa, and Teva’s Igalm.